90 related articles for article (PubMed ID: 8239515)
1. In vivo use of N-(4-hydroxyphenyl retinamide)-0-glucuronide as a breast cancer chemopreventive agent.
Abou-Issa H; Curley RW; Panigot MJ; Wilcox KA; Webb TE
Anticancer Res; 1993; 13(5A):1431-6. PubMed ID: 8239515
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapeutic evaluation of N-(4-hydroxyphenyl) retinamide-O-glucuronide in the rat mammary tumor model.
Abou-Issa H; Curley RW; Panigot MJ; Tanagho SN; Sidhu BS; Alshafie GA
Anticancer Res; 1997; 17(5A):3335-9. PubMed ID: 9413168
[TBL] [Abstract][Full Text] [Related]
3. Chemopreventive activity of a C-glucuronide analog of N-(4-hydroxyphenyl) retinamide-O-glucuronide against mammary tumor development and growth.
Abou-Issa HM; Alshafie GA; Curley RW; Wong MF; Clagett-Dame M; Repa JJ; Sikri V
Anticancer Res; 1999; 19(2A):999-1004. PubMed ID: 10368645
[TBL] [Abstract][Full Text] [Related]
4. Chemopreventive activities of C-glucuronide/glycoside analogs of retinoid-O-glucuronides against breast cancer development and growth.
Curley RW; Abou-Issa H; Panigot MJ; Repa JJ; Clagett-Dame M; Alshafie G
Anticancer Res; 1996; 16(2):757-63. PubMed ID: 8687125
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapeutic evaluation of 4-hydroxybenzylretinone (4-HBR), a nonhydrolyzable C-linked analog of N-(4-hydroxyphenyl) retinamide (4-HPR) against mammary carcinogenesis.
Abou-Issa H; Curley RW; Alshafie GA; Weiss KL; Clagett-Dame M; Chapman JS; Mershon SM
Anticancer Res; 2001; 21(6A):3839-44. PubMed ID: 11911255
[TBL] [Abstract][Full Text] [Related]
6. Effect of short-term administration of N-(4-hydroxyphenyl)-all-trans-retinamide on chemically induced mammary tumors.
Silverman J; Katayama S; Radok P; Levenstein MJ; Weisburger JH
Nutr Cancer; 1983; 4(3):186-91. PubMed ID: 6221232
[TBL] [Abstract][Full Text] [Related]
7. Comparative chemopreventive activity of ibuprofen and N-(4-hydroxyphenyl) retinamide against the development and growth of rat mammary adenocarcinomas.
Alshafie GA; Harris RE; Robertson FM; Parrett ML; Ross M; Abou-Issa H
Anticancer Res; 1999; 19(4B):3031-6. PubMed ID: 10652588
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of mammary tumor growth by a novel nontoxic retinoid: chemotherapeutic evaluation of a C-linked analog of 4-HPR-glucuronide.
Alshafie GA; Walker JR; Curley RW; Clagett-Dame M; Highland MA; Nieves NJ; Stonerock LA; Abou-Issa H
Anticancer Res; 2005; 25(3c):2391-8. PubMed ID: 16082771
[TBL] [Abstract][Full Text] [Related]
9. Relative efficacy of glucarate on the initiation and promotion phases of rat mammary carcinogenesis.
Abou-Issa H; Moeschberger M; el-Masry W; Tejwani S; Curley RW; Webb TE
Anticancer Res; 1995; 15(3):805-10. PubMed ID: 7645962
[TBL] [Abstract][Full Text] [Related]
10. Enhanced inhibition of mammary carcinogenesis by combined treatment with N-(4-hydroxyphenyl)retinamide and ovariectomy.
McCormick DL; Mehta RG; Thompson CA; Dinger N; Caldwell JA; Moon RC
Cancer Res; 1982 Feb; 42(2):508-12. PubMed ID: 6459843
[TBL] [Abstract][Full Text] [Related]
11. Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid.
Udeani GO; Gerhauser C; Thomas CF; Moon RC; Kosmeder JW; Kinghorn AD; Moriarty RM; Pezzuto JM
Cancer Res; 1997 Aug; 57(16):3424-8. PubMed ID: 9270008
[TBL] [Abstract][Full Text] [Related]
12. Comparative ability of ibuprofen and N-(4-hydroxyphenyl)retinamide to inhibit development of rat mammary adenocarcinomas associated with differential inhibition of gene expression of cyclooxygenase isoforms.
Parrett ML; Abou-Issa HM; Alshafie G; Ross MS; Harris RE; Robertson FM
Anticancer Res; 1999; 19(6B):5079-85. PubMed ID: 10697514
[TBL] [Abstract][Full Text] [Related]
13. Sulfone metabolite of sulindac inhibits mammary carcinogenesis.
Thompson HJ; Jiang C; Lu J; Mehta RG; Piazza GA; Paranka NS; Pamukcu R; Ahnen DJ
Cancer Res; 1997 Jan; 57(2):267-71. PubMed ID: 9000566
[TBL] [Abstract][Full Text] [Related]
14. Putative metabolites derived from dietary combinations of calcium glucarate and N-(4-hydroxyphenyl)retinamide act synergistically to inhibit the induction of rat mammary tumors by 7,12-dimethylbenz[a]anthracene.
Abou-Issa HM; Duruibe VA; Minton JP; Larroya S; Dwivedi C; Webb TE
Proc Natl Acad Sci U S A; 1988 Jun; 85(12):4181-4. PubMed ID: 2967969
[TBL] [Abstract][Full Text] [Related]
15. Effects of lycopene-enriched tomato oleoresin on 7,12-dimethyl-benz[a]anthracene-induced rat mammary tumors.
Sharoni Y; Giron E; Rise M; Levy J
Cancer Detect Prev; 1997; 21(2):118-23. PubMed ID: 9101071
[TBL] [Abstract][Full Text] [Related]
16. Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis.
Abou-Issa HM; Alshafie GA; Seibert K; Koki AT; Masferrer JL; Harris RE
Anticancer Res; 2001; 21(5):3425-32. PubMed ID: 11848504
[TBL] [Abstract][Full Text] [Related]
17. Purple grape juice inhibits 7,12-dimethylbenz[a]anthracene (DMBA)-induced rat mammary tumorigenesis and in vivo DMBA-DNA adduct formation.
Jung KJ; Wallig MA; Singletary KW
Cancer Lett; 2006 Feb; 233(2):279-88. PubMed ID: 15878797
[TBL] [Abstract][Full Text] [Related]
18. Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats.
Ratko TA; Detrisac CJ; Dinger NM; Thomas CF; Kelloff GJ; Moon RC
Cancer Res; 1989 Aug; 49(16):4472-6. PubMed ID: 2525951
[TBL] [Abstract][Full Text] [Related]
19. Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites.
Sabichi AL; Xu H; Fischer S; Zou C; Yang X; Steele VE; Kelloff GJ; Lotan R; Clifford JL
Clin Cancer Res; 2003 Oct; 9(12):4606-13. PubMed ID: 14555536
[TBL] [Abstract][Full Text] [Related]
20. Growth suppression of human breast carcinoma cells in culture by N-(4-hydroxyphenyl)retinamide and its glucuronide and through synergism with glucarate.
Bhatnagar R; Abou-Issa H; Curley RW; Koolemans-Beynen A; Moeschberger ML; Webb TE
Biochem Pharmacol; 1991 May; 41(10):1471-7. PubMed ID: 1826840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
